Navigation Links
Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis
Date:6/10/2015

INDIANAPOLIS, June 10, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that five abstracts featuring data from three clinical studies and separate pharmacology studies for its investigational rheumatoid arthritis drug baricitinib will be presented at the 2015 annual meeting of the European League Against Rheumatism in Rome June 10-13. Lilly and Incyte previously released positive topline results for the RA-BEACON and RA-BUILD studies, both of which met their primary endpoint of ACR20 at 12 weeks as compared to placebo.

"Incyte is committed to translating R&D excellence into new medicines, and we are very pleased with the initial results from the Phase 3 trials program of baricitinib," said Rich Levy, M.D., chief drug development officer at Incyte Corporation.

"With the prevalence of rheumatoid arthritis worldwide, Lilly is excited to share further information about baricitinib with the scientific community,"said David Ricks, Lilly senior vice president, and president of Lilly Bio-Medicines. "Lilly remains committed to following the science to challenge convention and continuously improve outcomes."

Abstracts being presented are highlighted below or can be accessed on the EULAR website at http://www.congress.eular.org.

  • "Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, In Patients With Active Rheumatoid Arthritis (RA) And An Inadequate Response To TNF Inhibitors: Results Of The Phase 3 RA-BEACON Study" – M. Genovese
  • "Baricitinib, an Oral JAK1/JAK2 Inhibitor, in Patients With Active Rheumatoid Arthritis and an Inadequate Response to cDMARDs: Results of the Phase 3 RA-BUILD Study" – M. Dougados
  • "Effects Of Baricitinib On Multi Biomarker Disease Activity Scores And Their Components In A Phase 2b Study In Moderate-To-Severe Rheumatoid Arthritis Patients" – P. Taylor
  • "Effects Of Baricitinib, An Oral JAK1/JAK2 Inhibitor, On Patient-Reported Outcomes From A Phase 3 Study In Patients Who Have Had An Inadequate Response To Tumor Necrosis Factor Inhibitors" – J.S. Smolen
  • "Evaluation Of Potential Drug-Drug Interactions With Baricitinib" – C. Payne

About Baricitinib
Baricitinib is a once daily, oral, selective JAK1 and JAK2 inhibitor. There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases, suggesting that JAK inhibitors may be useful for the treatment of a broad range of inflammatory conditions. Baricitinib demonstrates approximately 100-fold greater potency of inhibition against JAK1 and JAK2 than JAK 3 in kinase assays.

In December 2009, Lilly and Incyte announced an exclusive worldwide license and collaboration agreement for the development and commercialization of baricitinib and certain follow-on compounds for patients with inflammatory and autoimmune diseases. Baricitinib is currently in Phase 3 clinical development for rheumatoid arthritis and Phase 2 development for psoriasis and diabetic nephropathy.

About Rheumatoid Arthritis
Rheumatoid arthritis is an autoimmune disease[i] characterized by inflammation and progressive destruction of joints.[ii] More than 23 million people worldwide suffer from RA.[iii] Approximately three times as many women as men have the disease. Patients and physicians indicate there remains an important opportunity to improve patient care. Current treatment of RA includes the use of non-steroidal anti-inflammatory drugs, oral disease-modifying anti-rheumatic drugs such as methotrexate, and injectable biological response modifiers that target selected mediators implicated in the pathogenesis of RA.[iv]

About Baricitinib Phase 3 Trials
Lilly and Incyte are conducting four pivotal Phase 3 clinical trials of baricitinib in patients with moderately-to-severely active rheumatoid arthritis to support regulatory submission in most countries. An additional Phase 3 study was initiated to support clinical development in China. The clinical trial program includes a wide range of patients including those who are methotrexate naïve, inadequate responders to methotrexate, inadequate responders to conventional disease-modifying anti-rheumatic drugs, or inadequate responders to TNF inhibitors. Four of these five pivotal studies are expected to be completed by the end of 2015. Patients completing any of the five Phase 3 studies can enroll in a long-term extension study. For additional information on this clinical trial program, please visit www.clinicaltrials.gov.

About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics for oncology and inflammation. For additional information on Incyte, please visit the Company's web site at www.incyte.com.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels. (P-LLY)

This press release contains forward-looking statements about baricitinib as a potential treatment for patients with rheumatoid arthritis and reflects Lilly and Incyte's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results will be consistent with study findings to-date, or that baricitinib will receive regulatory approval. For further discussion of these and other risks and uncertainties, see Lilly's and Incyte's filings with the United States Securities and Exchange Commission. Lilly and Incyte undertake no duty to update forward-looking statements.

[i] American College of Rheumatology, Rheumatoid Arthritis, http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/ra.asp (Accessed: October 27, 2014)
[ii] Hand Clinics, Advances in the Medical Treatment of Rheumatoid Arthritis, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135413/pdf/nihms305780.pdf (Accessed: October 27, 2014)
[iii] WHO Global Burden of Disease Report, (table 7, page 32) 2004, http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf (Accessed Nov. 11, 2014)
[iv] Arthritis Foundation, Medications for Rheumatoid Arthritis, http://www.arthritistoday.org/about-arthritis/types-of-arthritis/rheumatoid-arthritis/treatment-plan/medication-overview/ra-medications.php (Accessed: May 15, 2013)

Refer to:                   
Celeste Stanley; celeste_stanley@lilly.com; +1-317-626-8896 (media)
Phil Johnson;  johnson_philip_l@lilly.com; +1-317-655-6874 (investors)
Michael Booth, DPhil; mbooth@incyte.com; +1-302-498-5914 (Incyte)     

 

Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO  
Logo - http://photos.prnewswire.com/prnh/20120608/DE21226LOGO


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Lillys Basal Insulin Peglispro Shows Superiority to Insulin Glargine in Reducing HbA1c in People with Type 2 Diabetes
2. Lilly commits 780,000 additional vials of insulin to Life for a Child
3. Lilly to Present Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology
4. Lilly to Participate in Goldman Sachs Global Healthcare Conference
5. Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors
6. Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities
7. Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data
8. Lilly Announces the Early Results of Its Cash Tender Offer
9. Lilly Sends Employees to Serve in Vulnerable Communities around the World
10. Lilly and Sanford-Burnham Announce Collaboration to Investigate Immunological Therapies
11. Lilly Announces Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities and the Redemption of Its 6.57% Notes due 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... September 11, 2019 , ... HOLLOWAY AMERICA, a leading manufacturer ... beverage to pharma and chemical, recently announced it will showcase its problem-solving vessels and ... , HOLLOWAY AMERICA’s first stop will be at ISPE San Diego’s 27th Life ...
(Date:9/11/2019)... ... 2019 , ... Pivot Point Consulting is excited to announce ... Partnerships team. Maris brings two decades of experience with Cerner—leading both sales ... as a Technical Implementation Leader representing the Technical Engagement Leader community. , Pivot ...
(Date:9/9/2019)... , ... September 09, 2019 , ... ... Shoreline Periodontics & Dental Implants host the latest course in their Synergy Study ... Mystic, CT and features guest speaker Dr. Peter Barndt. Synergy Study Club brings ...
Breaking Medicine Technology:
(Date:9/11/2019)... ... , ... Autopsies don’t lie. They report the causes of death as ... harms the heart. It increases risks of heart attack and death. Autopsies ... damage occurs. , An August 1, 2019 article in U.S. News ...
(Date:9/11/2019)... , ... September 10, 2019 , ... ... the team. Dr. Hesano is an understanding, caring and highly skilled Obstetrician/Gynecologist. ... obstetrical medicine. Dr. Hesano strives to ensure that each visit is comfortable, patient-focused, ...
(Date:9/9/2019)... ... September 09, 2019 , ... ST Engineering ... International will integrate the iDirect iQ 200 Board and the latest Evolution® software ... for first responders. The iQ 200 Board will enable the HARRIER solution to ...
(Date:9/9/2019)... ... September 09, 2019 , ... On ... organization-wide policy focusing on a diabetes-language movement (#LanguageMatters) to include oral and written ... non-judgmental, free from stigma, respectful and inclusive, empowering, and person-centered (to include care ...
(Date:9/8/2019)... ... 2019 , ... The reviews from patients of ABM Medical Clinic who have ... and pain free fat loss system, has patients booking their sessions and recommending this ... uses state of the art technology incorporating radio frequency and heat to rid the ...
Breaking Medicine News(10 mins):